Literature DB >> 23237880

Serum pentraxin 3 levels are associated with the complexity and severity of coronary artery disease in patients with stable angina pectoris.

Mehmet Fatih Karakas1, Eyup Buyukkaya, Mustafa Kurt, Sedat Motor, Adnan Burak Akcay, Sule Buyukkaya, Esra Karakas, Perihan Bilen, Nihat Sen.   

Abstract

BACKGROUND: Atherosclerosis is a complex inflammatory process in which inflammatory markers are involved. Although pentraxin 3 (PTX-3), a newly identified inflammatory marker, was associated with adverse outcomes in stable angina pectoris, no association between PTX-3 and the complexity of coronary artery disease (CAD) has been reported. Thus, the aim of the present study was to assess the association between the level of PTX-3 and the complexity and severity of CAD assessed with SYNTAX and Gensini scores in patients with stable angina pectoris.
METHODS: The study population consisted of 2 groups: 161 patients with anginal symptoms and evidence of ischemia who underwent coronary angiography and 50 age- and sex- matched control subjects without evidence of ischemia were included. Patients were grouped into 3 groups according to the complexity and severity of coronary lesions assessed by the SYNTAX score (30 patients with a SYNTAX score of 0 were excluded). Serum PTX-3 and high-sensitivity C-reactive protein (hs-CRP) levels were measured.
RESULTS: The PTX-3 levels demonstrated an increase from low to high SYNTAX groups (r = 0.72, P < 0.001). Whereas the low SYNTAX group had statistically significantly higher PTX-3 levels when compared with the control group (0.50 ± 0.01 vs 0.24 ± 0.01 ng/mL, P < 0.001), the hs-CRP levels were not different (0.81 ± 0.42 vs 0.86 ± 0.53 mg/dL, P = 0.96). However, the intermediate SYNTAX group had higher hs-CRP levels compared with the low SYNTAX group (1.3 ± 0.66 vs 0.86 ± 0.53 mg/dL, P = 0.002). Serum PTX-3 levels and hs-CRP levels were correlated with the SYNTAX scores and Gensini scores (for SYNTAX: r = 0.87 [P < 0.001] and r = 0.36 [P = 0.01]; for Gensini: r = 0.75 [P < 0.001] and r = 0.27 [P = 0.002], respectively), and according to the results of univariate and multivariate analyses, for "intermediate and high" SYNTAX scores, age, diabetes mellitus, low-density lipoprotein cholesterol, hs-CRP, and PTX-3 were found to be independent predictors, whereas for the presence of "high" SYNTAX score only PTX-3 was found to be an independent predictor. The receiver operating characteristic curve analysis further revealed that the PTX-3 level was a strong indicator of high SYNTAX score with an area under the curve of 0.91 (95% confidence interval, 0.86-0.96).
CONCLUSIONS: Pentraxin 3, a novel inflammatory marker, was more tightly associated with the complexity and severity of CAD than hs-CRP and was found to be an independent predictor for high SYNTAX score.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23237880     DOI: 10.2310/JIM.0b013e31827c2971

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  11 in total

1.  Associations between pentraxin 3 and severity of coronary artery disease.

Authors:  Hua Liu; Shaofeng Guan; Weiyi Fang; Fang Yuan; Min Zhang; Xinkai Qu
Journal:  BMJ Open       Date:  2015-04-08       Impact factor: 2.692

2.  Interesting Correlation Between the Circulating Pentraxin 3 and Cardiac Rehabilitation Program Outcomes in Coronary Artery Bypass Grafting Patients.

Authors:  Habib Haybar; Babak Payami; Isa Khaheshi; Yasaman Ghotbi; Seyed Mahmoud Latifi; Ahmadreza Assareh
Journal:  Cardiol Res       Date:  2016-05-04

3.  Serum neutrophil gelatinase-associated lipocalin levels are correlated with the complexity and the severity of atherosclerosis in acute coronary syndrome.

Authors:  Korhan Soylu; Gökhan Aksan; Gökay Nar; Metin Özdemir; Okan Gülel; Sinan İnci; Aytekin Aksakal; Ayşegül İdil Soylu; Özcan Yılmaz
Journal:  Anatol J Cardiol       Date:  2014-07-16       Impact factor: 1.596

4.  Pentraxin-3 Levels Relate to the Wells Score and Prognosis in Patients with Acute Pulmonary Embolism.

Authors:  Haotian Yang; Jun Zhang; Ying Huan; Yawei Xu; Rong Guo
Journal:  Dis Markers       Date:  2019-03-12       Impact factor: 3.434

5.  PTX3: an inflammatory protein modulating ultrastructure and bioenergetics of human endothelial cells.

Authors:  Albino Carrizzo; Claudio Procaccini; Paola Lenzi; Clorinda Fusco; Francesco Villa; Serena Migliarino; Massimiliano De Lucia; Francesco Fornai; Giuseppe Matarese; Annibale A Puca; Carmine Vecchione
Journal:  Immun Ageing       Date:  2019-02-02       Impact factor: 6.400

6.  CircSLC8A1 and circNFIX can be used as auxiliary diagnostic markers for sudden cardiac death caused by acute ischemic heart disease.

Authors:  Meihui Tian; Jiajia Xue; Cuiyun Dai; Enzhu Jiang; Baoli Zhu; Hao Pang
Journal:  Sci Rep       Date:  2021-02-25       Impact factor: 4.379

7.  Higher Plasma Pentraxin-3 Level Predicts Adverse Clinical Outcomes in Patients With Coronary Artery Disease: A Meta-Analysis of Cohort Studies.

Authors:  Kejun Ding; Zhewei Shi; Caizhen Qian; Xuan Yang
Journal:  Front Cardiovasc Med       Date:  2022-01-10

8.  HELP LDL apheresis reduces plasma pentraxin 3 in familial hypercholesterolemia.

Authors:  Michela Zanetti; Mariagrazia Zenti; Rocco Barazzoni; Federica Zardi; Annamaria Semolic; Michele Giuseppe Messa; Filippo Mearelli; Gianpaolo Russi; Maurizio Fonda; Luca Scarano; Enzo Bonora; Luigi Cattin
Journal:  PLoS One       Date:  2014-07-11       Impact factor: 3.240

9.  Pentraxin 3 Is Highly Specific for Predicting Anatomical Complexity of Coronary Artery Stenosis as Determined by the Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery Score.

Authors:  Mohammad Hasan Namazi; Habibollah Saadat; Morteza Safi; Hossein Vakili; Saeed Alipourparsa; Mohammadreza Bozorgmanesh; Habib Haybar
Journal:  Korean Circ J       Date:  2014-07-25       Impact factor: 3.243

10.  Evaluation of pentraxin-3 level and its related factors in patients undergoing primary percutaneous coronary intervention.

Authors:  Saeed Alipour-Parsa; Habib Haybar; Mohammad Hasan Namazi; Morteza Safi; Isa Khaheshi; Mehdi Memaryan; Amir Mohammad Eghbalnejad-Mofrad
Journal:  ARYA Atheroscler       Date:  2017-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.